Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma
Active, not recruiting · NCT05252429 · Registry updated 2025-09-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Site, neoplasm | Active, not recruiting | Phase 2 | 2025-09-12 | NCT05252429 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hokkaido University Hospital | 4 |
| Merck Sharp & Dohme LLC | 650 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hokkaido University Hospital | Sapporo | Japan | 9 |